Mallinckrodt Opioid Bankruptcy 2025 : It Paid Victims Twice, and Cut Both Times │ File 163 T1

This episode is part of Financial Forensics Labs — two shows, one forensic methodology: The Due Diligence Files traces how institutions collapse, The Signal Files traces how the good calls get made. Built from primary-record research by a 15-year capital markets professional. Get to know the framework, the other show, and the tools built from it — all in one place. Explore ⁠⁠⁠Financial Forensics Labs — Forensic Finance Intelligence⁠⁠⁠

Mallinckrodt promised $1.6 billion to the victims of the opioid crisis. It negotiated that settlement before it ever filed for bankruptcy, walked through Chapter 11 with the deal already signed, and emerged in 2022 looking like one of the rare opioid cases where victims would actually get paid. Fourteen months later, it filed for bankruptcy again. This episode traces the full arc: Mallinckrodt, the largest generic opioid manufacturer in the US, facing more than 3,000 lawsuits from states, counties, and individuals. In February 2020, months before filing, it reached a tentative $1.6 billion settlement with 47 state attorneys general — against a company-estimated total liability of up to $10 billion. The bankruptcy that followed in October 2020 was pre-arranged, built to move fast because the hardest negotiating had already happened. The plan was confirmed in 2022. Then, by June 2023, Mallinckrodt told the opioid trust it couldn't make a scheduled $200 million payment — while a group of hedge funds, including Silver Point Capital, negotiated to take control of the company through a second Chapter 11 filing. The deal: one final $250 million payment to close out the trust's remaining $1.275 billion claim, and roughly $1 billion of what victims and state governments were promised would simply be discharged. The payment landed on August 24th, 2023. Four days later, Mallinckrodt filed its second bankruptcy in three years. A judge approved it in October, calling it "a reasonable exercise of business judgment." By early 2025, Mallinckrodt was one of the only opioid companies actually paying individual victims — ahead of Purdue Pharma. After administrative fees and attorney costs, those payouts landed between $400 and $700 each. The hedge funds who engineered the second filing walked away holding equity in a reorganized company worth close to $3 billion. Two years later, Mallinckrodt merged with Endo — another opioid-bankruptcy alum — into a $6.7 billion combined company. Every step was legal. Every disclosure was public. This is what happens when bankruptcy stops being an emergency exit and becomes a scheduled tool a company can use twice. Every collapse has a pattern. We dissect it. Layer by layer. Keywords: Mallinckrodt bankruptcy, Mallinckrodt opioid settlement, opioid crisis lawsuits, Chapter 11 mass tort, opioid trust payout, Silver Point Capital, pre-packaged bankruptcy, second bankruptcy hedge funds, opioid victims compensation, distressed debt restructuring, Purdue Pharma comparison, opioid manufacturer lawsuit, generic drug company bankruptcy, mass tort settlement, bankruptcy court restructuring, corporate liability engineering, financial forensics podcast, forensic accounting case study, private credit due diligence, Endo Mallinckrodt merger, opioid epidemic accountability, bankruptcy business judgment standard, contingent value rights, opioid claimant trust, restructuring support agreement, corporate bankruptcy strategy, financial autopsy, Financial Forensics Labs, mass tort bankruptcy pattern, opioid manufacturer settlement, drug company litigation